Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial
Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial
Amalia Ndoutoumou, Robert Fenner, Aneet Gill, Emilia Caverly et al.
Citations
56 citations
Journal
The Lancet
Topics
Atrial Fibrillation Management and Outcomes
Field-Weighted Citation Impact (FWCI)
22.51
article
Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial
Amalia Ndoutoumou, Robert Fenner, Aneet Gill, Emilia Caverly, Archana Jayanthi, Nick Freemantle, Caroline J Doré, Liz Arram, Maryam Balogun, Kate Bennett, Ekaterina Bordea, Philip S. Nash, Nikola Sprigg, Rachael Hunter, Macey L. Murray, Stefan T. Engelter, Gary A. Ford, Bo Norrving, Norin Ahmed, Thuva Vanniyasingam, Jonathan G. Best, Hakim‐Moulay Dehbi, Martin James, David John Werring, Marisa Chau, David Cohen, Gregory Y.H. Lip, Hannah Sims, Mairead Cullen, Sue Massingham, Iwona Mazurczak
article en
56 citations
Abstract
No abstract available for this paper.
Publication Tag
The LancetVol. 404(10464)
Institutions
University of Nottingham (GB), University of Basel (CH), MRC Clinical Trials Unit at UCL (GB), Institute of Mental Health (GB), Felix Platter-Hospital (CH), Skåne University Hospital (SE), National Hospital for Neurology and Neurosurgery (GB), Comprehensive Clinical Trials (US), University College London (GB)
Funders
National Institute for Health and Care Research, British Heart Foundation